| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15651 R64618 |
Blotière (Indications other than epilepsy), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: No (among antiseizure medications) | 0.58 [0.04;9.35] C | 0/980 1,637/1,875,733 | 1,637 | 980 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15601 R64294 |
Tinker (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) | 1.00 [0.40;2.60] | 6/27 3,080/14,592 | 3,086 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17865 R75459 |
Eros (Indications NOS), 2002 | Cleft lip /- palate | during pregnancy (anytime or not specified) excluded | case control | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched |
no data excluded (exposition period) |
1/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 0.95 [0.39;2.30] | 4,723 | 1,007 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Indications other than epilepsy; 2: Mixed indications;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded